secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001193125-23-209005
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Q2 net loss $41.0M; PDUFA dates Oct/Nov 2023 for VOQUEZNA
-----------------------------------------------------------------

- Net loss $41.0M in Q2 2023, improved from $50.9M in Q2 2022.
- Cash $248.8M at June 30; $100M available from Hercules on Oct 1, $175M upon Erosive GERD approval.
- FDA PDUFA dates: Oct 30 for VOQUEZNA H. pylori packs; Nov 17 for Erosive GERD NDA.
- Completed public offering May 2023 with $141.4M net proceeds.
- Phase 3 PHALCON-NERD-301 completed; regulatory submission for Non-Erosive GERD on track H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523209005/0001193125-23-209005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523209005/d491223d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-209005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer